Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BioVersys

Request full access

Privately held Swiss biopharmaceutical company

Basel, SwitzerlandFounded 2010Biotech & Life Sciences

About BioVersys

BioVersys is a Swiss pharmaceutical company based in Basel, specializing in the research and development of small molecules targeting antimicrobial resistance (AMR). The company focuses on creating therapies that address bacterial infections through novel modes of action and targets. BioVersys operates in the pharmaceutical and biotech sectors, serving healthcare systems globally by providing solutions to combat the silent pandemic of AMR. The business model revolves around advancing clinical trials and bringing effective treatments to market, thereby generating revenue through the commercialization of its pharmaceutical products. The company is governed by a board of directors with extensive experience in the pharma and biotech industries, ensuring strategic oversight and guidance. BioVersys is committed to improving patient outcomes and safeguarding global health by addressing one of the most pressing medical threats of our time.

Source: Dealroom company data

At a glance

Status
Operational
Employees
41
Open positions
None listed
Dealroom signal
92.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, Molecular, Spinout, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Nov 2025 $16M — Undisclosed ↗
IPOOther financing Feb 2025 $73M $195M Undisclosed ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

BioVersys website traffic

Latest recorded traffic for BioVersys is 4.1K monthly website visits, up 7.9% over the last three months. BioVersys's team grew 28.1% over the past year.

Latest monthly visits4.1K 3-month web change+7.9% 1-year team growth+28.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

BioVersys in the Basel ecosystem

Live from Dealroom

The BioVersys office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • EVA Basel
  • CARB-X

Series A1 investor entered at this stage

  • Business Angels Switzerland

Series B and later4 investors entered at this stage

  • European Investment Bank
  • AMR Action Fund
  • GSK
  • Guangzhou Industrial Investment Fund

Other known investors4 additional known investors

  • ETH Zurich
  • Mick Mende
  • Venture Kick
  • VentureLab
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See BioVersys’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.